Multiple Sclerosis Drugs - Turkey

Turkey

In Turkey, the Multiple Sclerosis Drugs market is anticipated to witness a significant increase in revenue, with projections indicating a reach of US$35.63m in 2024.
Furthermore, it is expected that this market will experience a steady annual growth rate of 0.82% from 2024 to 2029, resulting in a market volume of US$37.12m by 2029.
When comparing global markets, United States is expected to generate the highest revenue in this market, with a projected value of US$11,770.00m in 2024.
The demand for multiple sclerosis drugs in Turkey is steadily increasing, driven by a growing awareness of the disease and improved access to healthcare.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Multiple Sclerosis Drugs in Turkey has been on the rise in recent years.

Customer preferences: Patients with Multiple Sclerosis in Turkey seek medications that can effectively reduce the progression of the disease and improve their quality of life. They prefer drugs that are affordable, easily accessible, and have minimal side effects.

Trends in the market: The market for Multiple Sclerosis Drugs in Turkey is growing due to the increasing prevalence of the disease in the country. The Turkish Ministry of Health has been taking steps to improve access to medication for patients with Multiple Sclerosis by including them in the reimbursement list. This has led to an increase in demand for these drugs. Furthermore, the introduction of new drugs in the market has also contributed to the growth of the market.

Local special circumstances: Turkey has a high prevalence of Multiple Sclerosis, with approximately 30,000 patients in the country. The disease is more common in women than in men, and it usually affects people between the ages of 20 and 40. The high prevalence of the disease in the country has led to an increased demand for medication.

Underlying macroeconomic factors: The Turkish pharmaceutical market is one of the fastest-growing in the world. The country's large population and growing economy have contributed to the growth of the market. The government has been investing in the healthcare sector, which has led to the development of new hospitals and clinics. This has improved access to healthcare services for the population, including patients with Multiple Sclerosis. The increasing disposable income of the population has also contributed to the growth of the market as patients are able to afford the medication.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.